China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
This article was originally published in PharmAsia News
SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process
You may also be interested in...
Despite a deepening economic slowdown and ongoing market access challenges, China overtook the U.S. as the top destination for expansion in a survey of global healthcare executives. Meanwhile, the 300-plus executives surveyed by UPS also rank regulatory hurdles above cost as the top barrier to expansion.
China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.
The Center for Drug Evaluation is making headway to improve the IND process, but it is still a long road ahead.